Syneron Bio: Valuation, Funding & Investors
Syneron Bio is a biotechnology company focused on the discovery and development of next-generation macrocyclic peptide therapeutics through its proprietary Synova™ platform. The company builds a robust pipeline targeting oncology and chronic diseases and leverages drug development expertise and data science to advance therapeutic candidates.
Leadership & Board
- Current Number of Employees
- 16
- Current LinkedIn Followers
- 457
Latest Estimated Valuation
- Total Amount Raised
- $250M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $150M
- Latest Funding Round
- Series B
Employee Trend
Syneron Bio had 16 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
16Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Syneron Bio had 457 followers as of October 26, 2026. The number of followers increased by 3 (0.66%) week-over-week.
457Latest Followers Count
3(0.66%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Apr 03, 2026 | Series B | $150.00M | ― |
| Dec 19, 2025 | Series A | $100.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Unnamed international life-science fund | Series B |
| Decheng Capital | Series B |
| CDH VGC | Series B |
| True Light Capital | Series B |
| Qiming Venture Partners | Series B |
| BioTrack Capital | Series B |
| AstraZeneca | Series B |
| LAV | Series B |
Similar Companies
A snapshot of private companies similar to Syneron Bio, helping you discover and navigate related company profiles.
Related News and Analysis
